Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Taipei Exchange - Delayed Quote TWD

Lumosa Therapeutics Co., Ltd. (6535.TWO)

Compare
158.00
-4.50
(-2.77%)
At close: 1:30:24 PM GMT+8
Currency in TWD All numbers in thousands
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
39,154
39,154
56,916
26,642
17,362
Cost of Revenue
21,441
21,441
15,435
12,081
7,473
Gross Profit
17,713
17,713
41,481
14,561
9,889
Operating Expense
374,657
374,657
417,106
320,480
440,167
Operating Income
-356,944
-356,944
-375,625
-305,919
-430,278
Net Non Operating Interest Income Expense
9,244
9,244
10,439
5,171
3,197
Pretax Income
-436,836
-436,836
-250,086
-504,445
95,946
Tax Provision
--
--
248
36
--
Net Income Common Stockholders
-424,784
-424,784
-238,041
-494,661
95,946
Diluted NI Available to Com Stockholders
-424,784
-424,784
-238,041
-494,661
95,946
Basic EPS
-2.60
--
-1.47
-3.04
0.64
Diluted EPS
-2.60
--
-1.47
-3.04
0.64
Basic Average Shares
163,378.46
--
161,932.65
162,765.53
150,985.15
Diluted Average Shares
163,378.46
--
161,932.65
162,765.53
151,254.75
Total Expenses
396,098
396,098
432,541
332,561
447,640
Net Income from Continuing & Discontinued Operation
-424,784
-424,784
-238,041
-494,661
95,946
Normalized Income
-424,608
-424,608
-237,919.40
-494,661
95,946
Interest Income
9,431
9,431
10,486
5,320
3,457
Interest Expense
187
187
47
149
260
Net Interest Income
9,244
9,244
10,439
5,171
3,197
EBIT
-436,649
-436,649
-250,039
-504,296
96,206
EBITDA
-428,237
-428,237
-226,678
-482,131
128,308
Reconciled Cost of Revenue
21,441
21,441
15,435
12,081
7,473
Reconciled Depreciation
8,412
8,412
23,361
22,165
32,102
Net Income from Continuing Operation Net Minority Interest
-424,784
-424,784
-238,041
-494,661
95,946
Total Unusual Items Excluding Goodwill
-176
-176
-152
--
--
Total Unusual Items
-176
-176
-152
--
--
Normalized EBITDA
-428,061
-428,061
-226,526
-482,131
128,308
Tax Rate for Calcs
--
--
0
0
--
Tax Effect of Unusual Items
--
--
-30.40
--
--
12/31/2021 - 7/16/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers